Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)


30 Sep 2019


Poster Display session 3


Tumour Site

Urothelial Cancer


Jean-Michel Lavoie


Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249


J. Lavoie1, G. Vandekerkhove2, M. Annala3, S. Taavitsainen4, N.L. Sundahl5, S. Walz6, T. Sano2, D. Khalaf1, T. Todenhöfer6, P. Ost7, C.K. Kollmannsberger1, K.N. Chi1, P.C. Black2, A.W. Wyatt2, B.J. Eigl1

Author affiliations

  • 1 Medical Oncology, BC Cancer - Vancouver, v5z 4e6 - Vancouver/CA
  • 2 Urologic Sciences, Vancouver Prostate Centre, V6H 3Z6 - Vancouver/CA
  • 3 Faculty Of Medicine And Health Technology, Tampere University, 33100 - Tampere/FI
  • 4 Biomeditech Institute, University of Tampere, 33520 - Tampere/FI
  • 5 Radiation Oncology And Experimental Cancer Research, Gent University Hospital, 9000 - Gent/BE
  • 6 Urology, Eberhard-Karls-University, 72076 - Tuebingen/DE
  • 7 Radiation Oncology, UZ Gent, 9000 - Gent/BE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3564


The therapeutic landscape for mUC is rapidly evolving, with the introduction of immune checkpoint inhibitors (CPIs) and targeted therapies providing new options. Prognostic and predictive biomarkers are urgently needed to facilitate clinical decision-making. In this setting, ctDNA is a non-invasive method for genomic profiling, but its clinical utility remains largely untested.


Whole blood samples were collected for next-generation sequencing of leukocyte and cell-free DNA (cfDNA). Deep targeted sequencing was performed across a UC-specific custom 50-gene panel to a median unique read depth of 1040x for cfDNA. Clinical records were reviewed for baseline characteristics and outcomes.


From 12/2014 until 11/2018, 103 patients with mUC underwent blood collection for cfDNA analysis. Of these, 84 had detectable ctDNA. Baseline characteristics and outcomes are presented in the table below for the entire cohort, along with exploratory analyses for patients who received platinum-based chemotherapy or a CPI in the metastatic setting. For cases with ctDNA>1%, selected results based on the presence or absence of mutations (muts.) in TP53 and ERCC2, as well as tumour mutation burden (TMB), are included.Table:


All cases (N = 103)
Median age (range)67 (37-88)
Male (%)83
Smoker (%)63
Median ctDNA (%)15.7
Median overall survival (OS, months)PresentAbsentP-value
ctDNA > median6.215.70.018
TP53 mut.16.927.10.082
ERCC2 mut.31.619.60.097
Platinum-treated (N = 54)
Carboplatin (%)37
First-line (%)89
Median progression-free survival (PFS, months)PresentAbsentP-value
TP53 mut.
ERCC2 mut.
CPI-treated (N = 50)
Combination with CTLA-4 (%)10
First-line (%)54
Median PFS (months)PresentAbsentP-value
TP53 mut.
ERCC2 mut.
TMB > 25 mut./Mb4.42.90.67


In our mUC cohort, the presence of ctDNA fraction above median correlated with worse OS, while mutations in ERCC2 correlated with improved PFS for platinum-treated patients. These data support the further exploration and validation of ctDNA as a tool for biomarker development in mUC. Additional analyses will be presented for the entire 50-gene panel.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Canadian Institutes of Health Research (CIHR) Bladder Cancer Canada (BCC).


J. Lavoie: Honoraria (self): Astellas. N.L. Sundahl: Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: BMS. D. Khalaf: Advisory / Consultancy: Bayer. T. Todenhöfer: Advisory / Consultancy: MSD; Advisory / Consultancy: Roche; Advisory / Consultancy: BMS. C.K. Kollmannsberger: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Eisai; Honoraria (self), Advisory / Consultancy: Ipsen; Advisory / Consultancy: Janssen; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Roche. K.N. Chi: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Essa; Advisory / Consultancy: Amgen; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Roche; Research grant / Funding (institution): Tokai Pharmaceuticals; Research grant / Funding (institution): Lilly/ImClone; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Merck. B.J. Eigl: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Zomanex; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Research grant / Funding (institution): Astellas; Honoraria (self), Research grant / Funding (institution): Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.